当前位置: X-MOL 学术J. Diabetes Investig. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.
Journal of Diabetes Investigation ( IF 3.2 ) Pub Date : 2020-03-11 , DOI: 10.1111/jdi.13219
Keizo Kanasaki 1, 2, 3
Affiliation  

N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ‐protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable antifibrotic peptide. The antifibrotic mechanism of AcSDKP is not yet clear; we have established that AcSDKP could target endothelial–mesenchymal transition program through the induction of the endothelial fibroblast growth factor receptor signaling pathway. Also, recent reports suggested the clinical significance of AcSDKP. The aim of this review was to update recent advances of the mechanistic action of AcSDKP and discuss translational research aspects.

中文翻译:

N-乙酰基-丝氨酰-天冬氨酰-赖氨酰脯氨酸是一种用于糖尿病肾纤维化的有价值的内源性抗纤维化肽:更新和翻译方面。

N-乙酰基-丝氨酰-天冬氨酰-赖氨酰-脯氨酸(AcSDKP)是一种内源肽,已被证实具有出色的器官保护作用。尽管最初被发现是造血干细胞的调节剂,但在最近的二十年中,AcSDKP被认为是有价值的抗纤维化肽。AcSDKP的抗纤维化机制尚不清楚。我们已经确定,AcSDKP可以通过诱导内皮成纤维细胞生长因子受体信号通路来靶向内皮-间质转化程序。另外,最近的报道提示了AcSDKP的临床意义。这篇综述的目的是更新AcSDKP的机械作用的最新进展并讨论翻译研究方面。
更新日期:2020-03-11
down
wechat
bug